Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
Solid Tumors
DRUG: IBI3020
Numbers of subjects with adverse events, defined as any untoward medical occurrence, whether or not there is a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed, Up to 3 years|Number of subjects with clinically significant changes in physical examination results, Clinically significant abnormal physical examination findings reported by the investigator., Up to 3 years|Number of subjects with clinically significant changes in electrocardiogram, Clinically significant abnormal electrocardiogram findings reported by the investigator., Up to 3 years|Number of subjects with clinically significant changes in vital signs, Vital signs including body temperature, pulse, respiratory rate, oxygen saturation by pulse oximetry at rest and blood pressure, Up to 3 years|Dose limiting toxicities (DLTs), Dose limiting toxicities (DLTs) to establish MTD and/or RP2D., Up to 21 days|objective response rate (ORR), objective response rate (ORR) as evaluated per the RECIST v1.1 criteria., Up to 3 years|Number of subjects with clinically significant changes in laboratory parameters, Clinically significant abnormal laboratory parameters findings reported by the investigator., Up to 3 years
area under the curve (AUC), area under the curve (AUC) of single and multiple doses of IBI3020, Up to 3 years|maximum concentration (Cmax), maximum concentration (Cmax) of single and multiple doses of IBI3020, Up to 3 years|time to maximum concentration (Tmax), time to maximum concentration (Tmax) of single and multiple doses of IBI3020, Up to 3 years|clearance (CL), clearance (CL) of single and multiple doses of IBI3020, Up to 3 years|apparent volume of distribution (V), apparent volume of distribution (V) of single and multiple doses of IBI3020, Up to 3 years|half-life (t1/2), half-life (t1/2) of IBI3020 to the last administration of IBI3020, Up to 3 years|anti-drug antibody (ADA), Incidence and characterization of anti-drug antibody (ADA)., Up to 3 years|objective response rate (ORR), objective response rate (ORR) as evaluated per the RECIST v1.1 criteria., Up to 3 years|duration of response (DoR), duration of response (DoR) as evaluated per the RECIST v1.1 criteria., Up to 3 years|time to response (TTR), time to response (TTR) as evaluated per the RECIST v1.1 criteria., Up to 3 years|progression free survival (PFS), as evaluated per the RECIST v1.1 criteria., Up to 3 years|disease control rate (DCR), disease control rate (DCR)as evaluated per the RECIST v1.1 criteria., Up to 3 years|overall survival (OS), OS is defined as the time from the date of first dose of study drug until the date of death from any cause., From date of randomization until the date of first documented date of death from any cause, assessed up to 36 months
The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.